SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging as investors react to SEC filings regarding executive change-of-control agreements, which are being widely interpreted as a strategic precursor to a potential buyout. The community remains highly bullish, focusing on extreme short-squeeze conditions and high borrow fees while anticipating a clinical readout for the company's flagship oncology asset.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is facing heightened volatility and investor scrutiny as the community closely monitors a high-stakes legal battle over distribution rights for its Duchenne muscular dystrophy candidate, Deramiocel. Investors are balancing concerns over litigation delays against optimism for an upcoming FDA PDUFA date and strong clinical data, with many advocating to treat recent price dips as a buying opportunity.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is seeing heavy community debate as investors weigh the stock's multi-year lows against potential catalysts like tariff refunds and an upcoming leadership transition. While some traders are betting on a turnaround ahead of earnings, others remain cautious of structural issues and negative analyst sentiment.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is seeing significant momentum and bullish sentiment following a strong earnings report, with the community celebrating the company's shift toward high-growth software and QNX-powered physical AI. Investors are actively discussing upcoming catalyst opportunities and potential institutional re-ratings, pushing back against skeptics while maintaining conviction in the long-term turnaround.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is trending as investors weigh its critical role in powering the AI data center boom against broader market volatility and recent project delays. The community remains divided, with long-term bulls highlighting its essential grid-bypass technology and massive backlog, while skeptics focus on valuation concerns and recent technical pullbacks.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is currently seeing high volatility and intense community discussion as investors weigh promising Ibsrela growth and strong fundamentals against persistent legal and reimbursement headwinds from the CMS bundling dispute. While some shareholders remain bullish on the long-term potential for profitability and acquisition, others are expressing frustration over stagnant price action and the ongoing regulatory uncertainty.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is trending due to the announcement of a $6 billion share repurchase program, which has sparked investor interest and fueled discussions regarding the company's valuation and long-term outlook. Community sentiment is mixed, with some traders viewing the buyback as a sign of management's confidence and an opportunity for value, while others remain skeptical, focusing on broader automotive market headwinds and the stock's recent performance.

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

AtaiBeckley Inc.

ATAI is experiencing heightened volatility and investor speculation as the market anticipates the potential allocation of FDA priority vouchers following recent executive orders supporting psychedelic therapy. The community is closely monitoring trial milestones for lead assets like BPL-003 and actively debating the stock's valuation disconnect and potential for a strategic partnership or buyout.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is currently experiencing high volatility and increased retail interest driven by speculation regarding its potential inclusion in the Russell 1000 index, which could trigger significant passive buying. The community is actively discussing the company's long-term potential in cancer immunotherapy, recent institutional buying, and the heavy short interest that has led many traders to anticipate a potential short squeeze.

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.

Transmedics Group Inc

Transmedics Group is trending as investors react to a significant post-earnings volatility, with the community actively debating whether the decline is a temporary margin squeeze driven by aggressive infrastructure expansion or a signal of structural revenue concerns. While short-term sentiment remains cautious due to technical selling and broader sector headwinds, long-term investors are highlighting strong flight data and the company's expanding market share as core pillars of the ongoing growth thesis.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

DMK Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets. It offers the SYMJEPI Injection for the emergency treatment of allergic reactions. The company was founded in June 2006 and is headquartered in San Diego, CA.

DMK Pharmaceuticals Corp

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

DMKPQAdamis Pharmaceuticals Corp

Fundamentals

Latest DMKPQ News